March 10, 2020

Robert B. Kay
Chief Executive Officer
iBio, Inc.
600 Madison Avenue, Suite 1601
New York, New York 10022

       Re: iBio, Inc.
           Registration Statement on Form S-3
           Filed February 28, 2020
           File No. 333-236735

Dear Mr. Kay:

       We have limited our review of your registration statement to those
issues we have
addressed in our comments. In some of our comments, we may ask you to provide
us with
information so we may better understand your disclosure.

       Please respond to this letter by amending your registration statement
and providing the
requested information. If you do not believe our comments apply to your facts
and
circumstances or do not believe an amendment is appropriate, please tell us why
in your
response.

       After reviewing any amendment to your registration statement and the
information you
provide in response to these comments, we may have additional comments.

Registration Statement on Form S-3 filed on February 28, 2020

Coverpage

1.     It appears that you are relying on General Instruction I.B.6 of Form
S-3. If true, please
       revise your prospectus cover page to disclose the calculation of the
aggregate market
       value of your outstanding voting and nonvoting common equity and the
amount of all
       securities offered pursuant to General Instruction I.B.6 during the
prior 12 calendar month
       period that ends on, and includes, the date of the prospectus. Refer to
Instruction 7 to
       General Instruction I.B.6. Otherwise, please provide us your analysis
demonstrating your
       eligibility to use Form S-3.
 Robert B. Kay
FirstName LastNameRobert B. Kay
iBio, Inc.
Comapany2020
March 10, NameiBio, Inc.
Page 2
March 10, 2020 Page 2
FirstName LastName
Description of Debt Securities, page 10

2.       We note the you are registering debt securities and that the
prospectus and legal opinion
         reference indentures. Please amend your registration statement to file
a form of indenture
         as an exhibit to your filing. For further guidance, refer to
Interpretations 201.02 and
         201.04 of our Trust Indenture Act of 1939 Compliance and Disclosure
Interpretations.
General

3.       We refer to your February 3, 2020 press release concerning your
collaboration with
         Beijing CC-Pharming Ltd. to develop and test a new 2019-nCoV vaccine
to be
         manufactured using your FastPharming System(TM). Accordingly, please
revise the
         prospectus to address corporate developments concerning the
coronavirus, or explain why
         this information is not material to investors. In addition, please
disclose the material terms
         of the collaboration agreement referenced in your February 3 press
release and file it as an
         exhibit to your filing, or explain why it is not material to an
investment decision.
        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.

       Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration
statement.

      Please contact Paul Fischer, Staff Attorney, at 202-551-3415, or Joseph
McCann, Legal
Branch Chief, at 202-551-6262, with any questions.



                                                                Sincerely,

                                                                Division of
Corporation Finance
                                                                Office of Life
Sciences
cc:      Andrew Abramowitz, Esq.